The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies
Abstract
The traditional view holds that apoptosis is non-immunogenic and does not induce an inflammatory response. However, recent studies have suggested that certain chemotherapeutic drugs that induce tumor cell apoptosis can induce immunogenic cell death (ICD) in cancer cells. This process is characterized by not only up-regulation of a series of signaling molecules in cancer cells, including expose of calreticulin (CRT), secretion of adenosine triphosphate (ATP) and release of high mobility group box 1 (HMGB1). In this review, we summarize recent progress in identifying and classifying ICD inducers; concepts and molecular mechanisms of ICD; and the impact and potential applications of ICD in clinical studies. We also discuss the contributions of ICD inducers in combination with other anticancer drugs in clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Programmed Cell Death in Animal Development and Disease
Fuchs, Y., & Steller, H. (2011) · Cell · doi:10.1016/j.cell.2011.10.033 · Cited by 1,915
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
How dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Plasma membrane changes during programmed cell deaths
Zhang, Y., Chen, X., Gueydan, C., & Han, J. (2018) · Cell Research · doi:10.1038/cr.2017.133 · Cited by 975
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 574
Molecular mechanisms of ATP secretion during immunogenic cell death
Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A. Q., Shen, S., Kepp, O., Métivier, D., Galluzzi, L., Perfettini, J.-L., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.75 · Cited by 563
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2
Chen, J., Xie, J., Jiang, Z., Wang, B., Wang, Y., & Hu, X. (2011) · Oncogene · doi:10.1038/onc.2011.137 · Cited by 512
Programmed cell death and the immune system
Nagata, S., & Tanaka, M. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.153 · Cited by 512
Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W. K., Zhou, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5643 · Cited by 500
Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452
Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003807 · Cited by 423
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 420
Martins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Bezu, L., Gomes-de-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 390
Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412096 · Cited by 386
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
Li, Y., Zou, L., Li, Q., Haibe-Kains, B., Tian, R., Li, Y., Desmedt, C., Sotiriou, C., Szallasi, Z., Iglehart, J. D., et al. (2010) · Nature Medicine · doi:10.1038/nm.2090 · Cited by 352
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death
Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., Fimia, G. M., Kepp, O., Piacentini, M., Froehlich, K.-U., et al. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.67 · Cited by 344
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292
Chemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278
Garg, A. D., & Agostinis, P. (2014) · Photochemical & Photobiological Sciences · doi:10.1039/c3pp50333j · Cited by 276
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
Yamazaki, T., Hannani, D., Poirier-Colame, V, Ladoire, S., Locher, C., Sistigu, A., Prada, N., Adjemian, S., Catani, J. P., Freudenberg, M., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.72 · Cited by 262
Inducers of immunogenic cancer cell death
Dudek, A. M., Garg, A. D., Krysko, D. V., De Ruysscher, D., & Agostinis, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.005 · Cited by 250
eIF2α phosphorylation is pathognomonic for immunogenic cell death
Bezu, L., Sauvat, A., Humeau, J., Gomes-da-Silva, L. C., Iribarren, K., Forveille, S., Garcia, P., Zhao, L., Liu, P., Zitvogel, L., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0044-9 · Cited by 241
Crosstalk between ER stress and immunogenic cell death
Kepp, O., Menger, L., Vacchelli, E., Locher, C., Adjemian, S., Yamazaki, T., Martins, I., Sukkurwala, A. Q., Michaud, M., Senovilla, L., et al. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.05.001 · Cited by 233
Miyamoto, S., Inoue, H., Nakamura, T., Yamada, M., Sakamoto, C., Urata, Y., Okazaki, T., Marumoto, T., Takahashi, A., Takayama, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3185 · Cited by 222
Suzuki, Y., Mimura, K., Yoshimoto, Y., Watanabe, M., Ohkubo, Y., Izawa, S., Murata, K., Fujii, H., Nakano, T., & Kono, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0851 · Cited by 219
Rossi, D., Terzi-di-Bergamo, L., De Paoli, L., Cerri, M., Ghilardi, G., Chiarenza, A., Bulian, P., Visco, C., Mauro, F. R., Morabito, F., et al. (2015) · Blood · doi:10.1182/blood-2015-05-647925 · Cited by 217
Anthracycline-Induced Cardiotoxicity: A Review of Pathophysiology, Diagnosis, and Treatment
Raj, S., Franco, V. I., & Lipshultz, S. E. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0315-4 · Cited by 196
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Tavora, B., Reynolds, L. E., Batista, S., Demircioglu, F., Fernandez, I., Lechertier, T., Lees, D. M., Wong, P.-P., Alexopoulou, A., Elia, G., et al. (2014) · Nature · doi:10.1038/nature13541 · Cited by 163
Baz, R. C., Martin, T. G., Lin, H.-Y., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A., Chari, A., Sullivan, D. M., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682518 · Cited by 159
Cartron, G., de Guibert, S., Dilhuydy, M., Morschhauser, F., Leblond, V., Dupuis, J., Mahé, B., Bouabdallah, R., Lei, G., Wenger, M., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586610 · Cited by 157
Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome, S. E., Voss, S. G., Wilcox, R. A., Wakefield, T. L., Tamada, K., Flies, D. B., Chapoval, A. I., Lu, J., Kasperbauer, J. L., Padley, D. J., et al. (2002) · PubMed · Cited by 153
Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy
Radogna, F., & Diederich, M. F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.006 · Cited by 149
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
Sukkurwala, A. Q., Adjemian, S., Senovilla, L., Michaud, M., Spaggiari, S., Vacchelli, E., Baracco, E. E., Galluzzi, L., Zitvogel, L., Kepp, O., et al. (2014) · OncoImmunology · doi:10.4161/onci.28473 · Cited by 144
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors
West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0890 · Cited by 137
Immunogenicity of anthracyclines: moving towards more personalized medicine
Apétoh, L., Mignot, G., Panaretakis, T., Kroemer, G., & Zitvogel, L. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.002 · Cited by 130
eIF2α phosphorylation as a biomarker of immunogenic cell death
Kepp, O., Semeraro, M., Pedro, J. M. B., Bloy, N., Buqué, A., Huang, X., Zhou, H., Senovilla, L., Kroemer, G., & Galluzzi, L. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.004 · Cited by 129
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research · doi:10.1186/bcr3175 · Cited by 122
Nam, G., Lee, E. J., Kim, Y. K., Hong, Y., Choi, Y., Ryu, M., Woo, J., Cho, Y., Ahn, D. J., Yang, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04607-9 · Cited by 117
The emergence of phox-ER stress induced immunogenic apoptosis
Garg, A. D., Krysko, D. V., Vandenabeele, P., & Agostinis, P. (2012) · OncoImmunology · doi:10.4161/onci.19750 · Cited by 110
Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death
Martins, I., Michaud, M., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Shen, S., Kepp, O., Menger, L., Vacchelli, E., Galluzzi, L., et al. (2012) · Autophagy · doi:10.4161/auto.19009 · Cited by 107
Lin, T.-J., Lin, H.-T., Chang, W.-T., Pradeep Mitapalli., S., Hsiao, P., Yin, S., & Yang, N. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0435-9 · Cited by 105
Cornelissen, R., Hegmans, J. P., Maat, A. P. W. M., Kaijen-Lambers, M. E. H., Bezemer, K., Hendriks, R. W., Hoogsteden, H. C., & Aerts, J. G. J. V. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1573oc · Cited by 105
Dudek-Perić, A. M., Ferreira, G. B., Muchowicz, A., Wouters, J., Prada, N., Martin, S., Kiviluoto, S., Winiarska, M., Boon, L., Mathieu, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2089 · Cited by 104
Obéid, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2533 · Cited by 98
Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance
Lin, S., Hsieh, S., Fan, Y.-T., Wei, W., Hsiao, P., Tsai, D.-H., Wu, T., & Yang, N. (2017) · Autophagy · doi:10.1080/15548627.2017.1386359 · Cited by 96
Self-citationGarrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003477 · Cited by 91
Immune Mechanism of the Antitumor Effects Generated by Bortezomib
Chang, C.-L., Hsu, Y.-T., Wu, C.-C., Yang, Y., Wang, C., Wu, T.-Q., & Hung, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103826 · Cited by 87
eIF2α phosphorylation: A hallmark of immunogenic cell death
Bezu, L., Sauvat, A., Humeau, J., Leduc, M., Kepp, O., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431089 · Cited by 87
Cirone, M., Renzo, L. D., Lotti, L. V., Conte, V., Trivedi, P., Santarelli, R., Gonnella, R., Frati, L., & Faggioni, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031732 · Cited by 86
Tanis, E., Julié, C., Emile, J., Mauer, M. E. L., Nordlinger, B., Aust, D. E., Roth, A. D., Lutz, M. P., Gruenberger, T., Wrba, F., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.014 · Cited by 83
Trial Watch: Adoptive cell transfer for anticancer immunotherapy
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24238 · Cited by 79
Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress
Garg, A. D., Maes, H., van Vliet, A. R., & Agostinis, P. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.975089 · Cited by 78
Lu, A., Pallero, M. A., Lei, W., Hong, H., Yang, Y., Suto, M. J., & Murphy-Ullrich, J. E. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.003 · Cited by 75
Colangelo, T., Polcaro, G., Ziccardi, P., Muccillo, L., Galgani, M., Pucci, B., Milone, M. R., Budillon, A., Santopaolo, M., Mazzoccoli, G., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.29 · Cited by 73
Select forms of tumor cell apoptosis induce dendritic cell maturation
Demaria, S., Santori, F. R., Ng, B., Liebes, L., Formenti, S. C., & Vukmanović, S. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0804478 · Cited by 67
Murahashi, M., Hijikata, Y., Yamada, K., Tanaka, Y., Kishimoto, J., Inoue, H., Marumoto, T., Takahashi, A., Okazaki, T., Takeda, K., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.03.015 · Cited by 66
Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma
Šanović, R., Verwanger, T., Hartl, A. J., et al. (2011) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2011.04.003 · Cited by 63
Gulhati, P., Raghav, K. P. S., Shroff, R. T., Varadhachary, G. R., Kopetz, S., Javle, M. M., Qiao, W., Wang, H., Morris, J. S., Wolff, R. A., et al. (2016) · Cancer · doi:10.1002/cncr.30445 · Cited by 63
Schumacher, L., Vo, D. D., Garbán, H., Comín-Anduix, B., Owens, S. K., Dissette, V. B., Glaspy, J. A., McBride, W. H., Bonavida, B., Economou, J. S., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4757 · Cited by 60
Brusa, D., Garetto, S., Chiorino, G., Scatolini, M., Migliore, E., Camussi, G., & Matera, L. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.08.063 · Cited by 59
Kumar, S. K., LaPlant, B. R., Reeder, C. B., Roy, V., Halvorson, A. E., Buadi, F. K., Gertz, M. A., Bergsagel, P. L., Dispenzieri, A. A., Thompson, M. A., et al. (2016) · Blood · doi:10.1182/blood-2016-05-717769 · Cited by 57
Geisler, C. H., Veer, M. B. V., Jurlander, J., Walewski, J. A., Tjønnfjord, G. E., Itälä‐Remes, M., Kimby, E. K., Kozák, T., Polliack, A., Wu, K. L., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547737 · Cited by 51
Garrido, G., Lorenzano, P., Sánchez, B., Beausoleil, I., Alonso, D. F., Pérez, R., & Fernandez, L. E. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0313-4 · Cited by 44
TFAM is a novel mediator of immunogenic cancer cell death
Yang, M., Li, C., Zhu, S., Cao, L., Kroemer, G., Zeh, H. J., Tang, D., & Kang, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431086 · Cited by 43
Trial Watch: Adoptive cell transfer for anticancer immunotherapy
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A. M. M., Galon, J., Fridman, W. H., Cremer, I., Tartour, É., Zitvogel, L., Kroemer, G., et al. (2014) · OncoImmunology · doi:10.4161/onci.28344 · Cited by 39
Chari, A., Htut, M., Zonder, J. A., Fay, J. W., Jakubowiak, A. J., Levy, J. B., Lau, K., Burt, S. M., Tunquist, B. J., Hilder, B. W., et al. (2016) · Cancer · doi:10.1002/cncr.30174 · Cited by 38
Stangl, S., Themelis, G., Friedrich, L., Ntziachristos, V., Sarantopoulos, A., Molls, M., Skerra, A., & Multhoff, G. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.051 · Cited by 36
Leone, F., Artale, S. A., Marino, D., Cagnazzo, C., Cascinu, S., Pinto, C., Fornarini, G., Tampellini, M., Fabio, F. D., Bianchi, A. S., et al. (2013) · Cancer · doi:10.1002/cncr.28223 · Cited by 32
Treatment of colon cancer with liver X receptor agonists induces immunogenic cell death
Wang, Q., Ren, M., Feng, F., Chen, K., & Ju, X. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22811 · Cited by 30
Self-citationWallach, D., & Kovalenko, A. (2014) · eLife · doi:10.7554/elife.02583 · Cited by 27
Hijikata, Y., Okazaki, T., Tanaka, Y., Murahashi, M., Yamada, Y., Yamada, K., Takahashi, A., Inoue, H., Kishimoto, J., Nakanishi, Y., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0187878 · Cited by 19
Carr-Brendel, V. E., Markovic, D., Smith, M. H., Taylor‐Papadimitriou, J., & Cohen, E. P. (1999) · Journal of Immunotherapy · doi:10.1097/00002371-199909000-00005 · Cited by 12
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Immunogenic Cell Death Induction by Ionizing Radiation
Zhu, M., Yang, M., Zhang, J., Yin, Y., Fan, X., Zhang, Y., Qin, S., Zhang, H., & Yu, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705361 · Cited by 291
Self-citationTipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death
Hayashi, K., Nikolos, F., Lee, Y. C., Jain, A., Tsouko, E., Gao, H., Kasabyan, A., Leung, H. E., Osipov, A., Jung, S. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19970-9 · Cited by 274
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Immunogenic Cell Death-Based Cancer Vaccines
Jin, M.-Z., & Wang, X.-P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697964 · Cited by 99
“have divided ICD inducer into two types: type I for those inducing ROS generation (chemotherapeutic agents/targeted therapy), type II for those inducing ER stress (PDT/Oncolytic viruses) (60).”
Background
Metadata
- Authors
- Wang, Q., Ju, X., Wang, J., Fan, Y., Ren, M., & Zhang, H.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 438
- Pages
- 17-23
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2889823397
- Cited by
- 264
- References
- 96
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.